ARCT - Earnings call transcript Q4 2021 | Arcturus Therapeutics Holdings Inc.

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Greetings. Welcome to the Arcturus Therapeutics Fourth Quarter and Full Year 2021 Earnings Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. [Operator Instructions]. is conference this note being recorded. Please now Deepankar Roy, will turn Relations. the host, your to over Senior conference I Director Investor of

You may begin.

Deepankar Roy

quarter and led Thank our Pad you Thank Arcturus for Andy joining Financial and Sassine, afternoon call all COO. Payne, and and will Sassine, President Today's fourth CEO. be results call. you. Dr. XXXX. Joseph full our CFO, update welcome corporate and us. CFO year by Good Therapeutics, to and

on like to this Securities that Please would Harbor unknown Form, assumptions differ been by and from everyone and that that and vary. to Before XX-K cause not the well in forward-looking during issued results the I we the uncertainties, are Litigation as see filed risks, it's Safe risk remind forward-looking Company's statements the made of performance may Performance. factors or XXXX, they within statements call our SEC. are involve the Private begin, you've And Act provisions disclaimer of the section earlier today, matters are those known regarding from the implied of statement. forward-looking not historical press facts as expressed with release statements materially actual guarantees statement

future views any any disclaims obligation such our addition, events February In to over Joe. forward-looking the circumstances. and statements statements the are our Arcturus specifically long-term to reflect only date XX, to of as information represent With statements call such XXXX are that, made, update

Joseph Payne

today. you quarterly afternoon Deepankar, joining you thank our call good thank Hey, for all [Indiscernible] to

on And programs that Disease on acknowledge national and diseases, a centric to that recognition. disease. is are Day, OTC day and liver cystic publicly families two like of we Before February is at today programs those to to gratitude pipeline all lung express this working patients fibrosis and just National and disease, the to wanted would clinicians rare rare my these I deficiency, that our diligently here begin, rare Rare are given Arcturus, XX, I of

update onto about our progress. Now our recent

continued targeting mRNA therapeutic make have programs begin candidates. of vaccine COVID-XX. to We progress vaccines advancing with based a I our and excellent discussion will our

ARCT-XXX XX protect we DXXXG SARS-CoV-X neutralizing a our that is increased the the recent low the five of a of of against concern. SARS-CoV-X strains Let's antibody and including program vaccine showing data dose and, only by data, begin that advanced designed most encouraging program against ancestral micrograms ARCT-XXX boosted with This is folds supported to clinical booster activity respectively. XX and omicron reported, by variant or

We for the Health announce Authorization biopharmaceutical our important completed company. for ARCT-XXX our are of to ARCT-XXX. the Use Application or has MRNA Emergency with and technology we integrated as a stage strive toward company, our collaborative platform. self-amplifying as mature a Vietnamese excited becoming an filing milestone This an star Vinbiocare Ministry product represents that today trademarks commercial very of global

very translation. of Beta, immunogenicity we from showed low least program, vaccine We of booster. at on phase data five platform profile when microgram a to includes rapidly ARCT-XXX multiple human high as -clinical its efficient pre announced administered antibody in observed that data variances concern based robust several highly study. ARCT-XXX been doses other phase in is this the We've X, relevant X/X in and is responses of These validated multiple wide its into has immunogenicity X, neutralizing clinical this assays. our modifications understanding efficacy, our as interest of clinical the studies. into booster addition ARCT-XXX substantial that encouraging candidate. the ARCT-XXX coverage half-life, for DXXXG results data to MRNA mutations vaccine our believe as modifications neutralization encouraging of this alternative and the candidates exploratory at X activity well We following especially ARCT-XXX variant against the of Earlier extend vaccine This program variances in of shown circulating months may confidence that initial these levels has and candidate ancestral, five and and the of this broad clinic also duration a XX designed expression. move against showed Delta in world. enable variances. across responses progressing XXX vaccine antigen variants neutralizing high of booster And proprietary immunity against addition, And with expeditiously an levels to this an quarter, respectively potential this two to with clinically and these in we and vaccination Incorporated circulating assay. using combined exploratory a in the improve range efficacy in designed vaccine Comirnaty, XX-fold with the developed robust and micro-neutralization we increases provide antibodies Omicron the models. In and T-cell of These for in clinical these stability provide others optimized and us increase sequence improved candidates and

for used So disease. data, a vaccination. We our of continuation explore or to for its primary in populations these is ARCT-XXX goal strong against use of by to as vaccination a seeking broadly or immunogenic supported severe that initiation can protection aim and currently vaccine as develop potential be booster COVID-XX

the Phase study The closely working -XXX collaborator ARCT Vietnam. against to immunogenicity the ARCT-XXX in X/X/X with include are and objectives efficacy infection. of We of of our safety, study operationalize evaluation Vinbiocare SARS-COV-X

trial X/X/XA of cohorts application to Efficacy the a be participants and was for doses of approval. X, ARCT-XXX days potential that the apart. subsequently two given [Indiscernible] EUA data application XX X, study, completed X,XXX or the of immunogenicity The Health All safety and from the data XC first of the cohorts Phase in will included Ministry XA, are XB Phase pivotal in today. all the from have the full submitted submitted in meaning

technology facility the We funded and in manufacturing deficiency support. grateful OTC that Hanoi doses trial therapeutic Vinbiocare's approved transfer no and continues global and that this the Hanoi, of manufacturing will In turn we Transcarbamylase rare I ARCT-XXX, is manufacturing to of the address addition, sponsored for cause development million candidate to everyone Vietnam now disease. for of capacity disease production by toward our and are OTC our remind anticipated the footprint is their to continues facility progress with fully per deficiency. to or mature serious Vinbiocare our indeed XXX and a treatments root year.

the the We administration study Transcarbamylase the for liver Our favorable healthy previously was prevent demonstrated neurological transplantation. and therapeutic candidate ARCT-XXX aims restore an X X-XX volunteer cycle completed and in enzyme tolerability liver dose attractive patients ARCT-XXX, with with profile. OTC associated that which pharmacokinetic Lipid activity, prevent and a to we're to need of the urea escalation Phase ARCT-XXX excipients normal has the damage, of expression potential in restore we no Phase deficiency. with delays. after longer preclinical complete to patients within is in estimated identifying first to I'm after are observed the additional have Xb range cohort based report quarter. second the clinically therapeutic hours. upon we related XX The in our And now plasma with that the doses anticipated now we're for evaluating studies. trial that happy dosing OTC expect COVID for the screening deficiency adults

multiple Belgium Kingdom research seeking We placebo Spain and is site randomized ascending and single participants. European for we double-blind ARCT-XXX. clinical two the expect nested continue United controlled half while OTC screening we of the authority, deficiency. to conduct would countries. activities in multiple a subset from from and approval will well a with study adolescents as obtained startup in a design X data second dose XXXX enroll health to additional as interim Phase a to initiate the trial dose commence And quarter, have authorization that in anticipate Phase XX This adults obtain second of with that in and We

Moving program. cystic fibrosis now our to

have in the clinical fibrosis application XXX is quarter - to candidate clinical into to necessary We XXXX. third pre mRNA a -XXX, of anticipate therapeutic ARCT the for our for studies move We enable studies. -clinical the cystic to this trial continued ARCT submission of progress

vaccine tremendous some mRNA clinical that selection the release. flu, often flu the with which gaps Our candidate progress believe in manufacturing towards required and have address We sub-optimal vaccines, self-amplifying to efficacy suffer from termed to lunar flu also program, promise and current vaccines continues development. lengthy

vaccines - have manufacturing processes advantage mRNA able adapted addition, through circulating potentially based being be rapid the more In flu currently strains. to to of mRNA much target

this application in expect lunar development year XXXX. with clinical a selection of We flu advanced trial candidate, STARR candidate toward a self-amplifying and platform a make to final our

The programs most companies, our J to including several In lunar internally addition evaluated therapeutic glycogen and pass a partnered is our also onto disease, programs, Ultragenyx leading being of and Ultragenyx by therapeutic the Arcturus has J these CFO. now Takeda. storage Andy, & the for developed which biopharmaceutical will very of programs a of X/X with promising some Phase advanced is in these call currently study. I candidate

Andy Sassine

Please today strategy provide performance. in and The as some over I will financial present late-stage go our XXXX And some XX-K a and for as in of to the assets clinical year year-over-year our issued more financial operating Emergency we company on release several earlier will Thank and we performance. for prepare regarding includes transition I for you, Joe. our summary quarter afternoon, sequential our good potential Use to fiscal reference details and financial a Vietnam. metrics also manufacturing Authorization continue statement everyone. the fourth financial and press analysis with the details the provides pipeline. of

and regarding our I Finally, cash expected insight position provide some run will rate.

variant and of booster in a is of and which for trial our Joe Vietnam a in with As program a results $XXX funding, ARCT-XXX savings mentioned, significant Bio manufacturing the targeting the corporations. heard, including dollars known, This you we our partnership, sponsoring XXX group, partnered our the in Vin including concern. trial cost Vietnam, in Biotech Hanoi, in Vinbiocare. completion the trial in in Vin U.S.A. productive and in ARCT-XXX you is and Have Vietnam's Vin human study very collaboration encouraging Singapore, clinical Vietnam XXXX, resulted COVID-XX Phase facility candidate was vaccine we million part QX the well COVID-XX of largest lunar next-generation over one vaccine our building of around and had of Arcturus.

Total the expenses, million decline $XX was research about XXXX, for $XX manufacturing for and with due global to the a necessary were other fourth year, CMC quarter operating to for Revenues increased technology we payment million and strategic the was $XX.X received costs Net declined sequentially of LUNAR-COV-XX from million, XXXX $X.X by of the partial manufacturing million expenses the due fourth primarily track in the for $XX million. the This fourth decline Vinbiocare regulatory was or was was and associated with this Europe, from due $XX.X to XXXX for This development $X.X alliances $XX programs, Japan, agreement. which collaboration XXX remain basic decline primarily U.S.A. filings. approximately our We're quarter manufacturing also This the loss the technology including activities clinical sequentially. on become doses was Our sequential the the approximately fourth per quarter mature partners with over annually. diluted including which later to operational million. capacity footprint, reduction facility share. of the work transfer in for million quarter continuing of and to $X.XX increase for million, of and of which requirements recognition million to transfer for

we loss and of diluted For $X.XX million share. reported basic net or per the $XXX approximately year, a

Our operations be pipeline, based Joe. current to the our sufficient cash $XXX.X of And will position our call expected end to support back now the into quarter million. was cash the late at I XXXX. on balance to fourth is pass

Joseph Payne

Hey, Andy. thanks,

I our can vaccines had As the time of quarter we've right questions. the back you, to pipeline Kyle, productive time RNA, therapeutics. advancing guess operator, now messenger to we over our to it's turn see, another and field

Operator

moment, question-and-answer questions. conducting One please, we you. At we'll this be [Operator a poll Instructions] session. Thank for while time,

your with Our question. with first Sandler. Rahimi Yasmeen from Piper proceed question is Please

Yasmeen Rahimi

much team. filed. the authorization congrats emergency for And you thank being on the afternoon, updates Good so and

that to the on you you which when can the should with had a now the -- to and some So far have behind your maybe present give have data Biocare? you -- you, chance when to us you review data and opportunity color at then partners so us would

Joseph Payne

question, in. Great for Yasmeen. Hey. calling Thanks

Vinbiocare. As the owned we that realized data by is

to want we so And acknowledge that.

We trial to of trial-blinded on we have and some the no of to unblinded data clinical portion XB have access to beyond. and access any no the had Phase but data, any data access kind

opportunities be after after Vinbiocare may data where and clearance they the of Health. data are. we get that Vietnam share that's So but Ministry the in publicly, future There with the to from share we

Yasmeen Rahimi

drill to been like, what's review long process? is this just And or then So it us maybe each days us? an process? can it? now get their Like we weeks it has for steps Joe, these give the of And before you just a idea because down share how wait question you many take how could before of timing does releasing like filed, with

Joseph Payne

additional Well, the QX submitted now successfully, EUA. at of approval approval, share presents or of pertaining data the -- that the to of approved, program. we the After are first that for point that been this has course, period there's of EUA before a this guiding to time, quarter gets opportunity that

order of near-term So think I the would those events. be

Yasmeen Rahimi

I sure make to Just understand.

of EUA disclose it's that is days Is you to us? it data matter the on say a the accepted. March soon as let's get as just can XXth, few you So accepted

Joseph Payne

It's ultimately that a but would the responsibility Vinbiocare. question under and fair appropriate be of

Of them and what's course work like to we'd share appropriate. with

Yasmeen Rahimi

Got it. Thank jump you. Thanks. into back I queue for will questions.

Joseph Payne

Yeah. Thanks. Yasmeen.

Operator

Thank you.

is from with Chang, question your proceed Please next with Cantor Brian question. Fitzgerald. Our

Brian Chang

for Thanks feedback program my regulator. fixation from Han. the question.XXX taking any Joe or Hey,

Joseph Payne

out Hey, little bit. a breaking in Brian, and you're

Brian Chang

Can me? you hear

Operator

Brian, proceed. Hey please

Joseph Payne

Please the question. repeat

Brian Chang

whether Can Thanks. on asset then to Yes. color a you think to any data you efficient, light booster. get you travel? on green some And for from for of feedback other you, boosters provide have

Joseph Payne

Sure.

strategy just And regulatory And So there to for trial frankly. question bit, the believe broke because we're approval process and repeat understand, but trying boosters. around little I globe, engaging multiple determining to in are up authorities I'm aligning for just your regulatory of the that. going you're it and requirements a we're real-time

have have that we communicate we that than feedback, and will that. there, So to alignment information, be we once able

Brian Chang

Okay.

by it through? one Just come of quarter piling time you Vingroup operated operational a stock the bit? one on on down And by facility Will Thanks. stockpiling. your that can where this you your R&D expense because that's comment terms the quick be Hanoi in EUA are come have seems fair

Joseph Payne

Sure.

the is with comment state and we're timing, assisting for facility inappropriate it's comment on effort. -- and in them continuously Vingroup state-of-the-art paying assisting to for us them So progressing. we But I is But specific can well, manufacturing of definitely funding updates facility to But being are process helping the that our And facility. the continuously respect that I the built. would guidance actively they're building. it provide for and their can be that that them in

looking a guidance. specific be when launch, them of In for that terms date just of it that. will to do would provide we'd inappropriate us It to to be

Brian Chang

Joe Thanks,

Joseph Payne

comment? And do you then Andy, another have

Andy Sassine

some be year. No, this facility my commentary I did the provide should later sometime in that color operational

they that'll hopefully anticipate help production. some So to with into you when going guidance give respect

Brian Chang

Andy. Thanks,

Andy Sassine

you. Thank

Operator

come now with next Wells question. your question Fargo. Our with will is It question line Please next has with Nick from your with disconnected. open. Fernandez And Fernandez, proceed from like Securities. your is Please Seamus Guggenheim looks Mr. Fernandez proceed Mr. our question. Abbott

Nick Abbott

congratulations much your to very the and you on EUA. and you partners Thank Terrific.

for you booster strategy mentioned types So obviously, presumably approval and Vinbio you about strategy market. as approval the would [Indiscernible] plans local mind well prime others? global has as a Joe, for be booster the strategy, the Can in series and talk Vietnam in a their for booster but

Joseph Payne

been eight approximately it vaccines to that this folks, their you approved the two -- right. so. with an boost is concerted locally. or appreciate now, provides population these as of past Vietnam can do But a vaccinated opportunity year to been They've really majority it's effort have

but Ministry in Health of engaged of that with we're also that facility. we respect application So we manufacturing EUA working disclosed in Vinbiocare our we've we're shared process. And have development Vietnam a with to haven't booster the disclosed on an Vietnam, with actively any strategy details the

but that, any being direct So timing there's some of guidance as provided indirect of to of any manufactured haven't distributed. the implications or sort we boosters

Nick Abbott

Thanks, Joe. Okay.

conducting a the assume could Vinbiocare trial reasonable Vietnam? it in to is be So booster

Joseph Payne

We regulatory is Ministry the with we of multiple talking what authorities, Yes. Vietnam including are disclosed we've Health. that

communicating agencies be with harmonize that we other trial there. Once right Singapore. have have trying alignment We U.S. requirements and there's and and collected And it. better to suited were and trials XXX regulatory information get we'll with, communicate active to the in that determining

Andy Sassine

more on some We plan finding clarity.

Joseph Payne

has a Andy Andy. comment too

Andy Sassine

on in clarity providing on plan quarter. later our more We for booster this our strategy

stay So tuned.

Joseph Payne

Yes.

Nick Abbott

Okay. to with data And share the then the outside the fact of Joe, you've that mentioned owned you Phase partners what potential the owned process for data X by data is the [Indiscernible] MN? is that by

Joseph Payne

some Phase see Well that we blinded to be data we've earlier opportunity potential data remain the but we trials example, encouraging. haven't had is the or with asking? clinical what blinded to to unblinded beyond, the seen have to that for partners, for of any you're that of the or freedom share And pertaining the XB

Nick Abbott

them with perhaps that you to hand that owning don't the obviously the mean, data, free I would Yes. share -- you data. otherwise have that

So that perhaps can. it's update outside on partners? with discussions potential of you can us with you But Vietnam encouraging

Joseph Payne

it's always Arcturus potential has strategic But that. on Well, with don't active always right? discussions give partners, to we its specific provide challenging guidance specific that. guidance in been on

Nick Abbott

Thanks. you. in the I Thank go queue. will Okay. back

Joseph Payne

calling Thanks, Nick. you I appreciate in.

Operator

Thank you.

proceed Kumar with question next Brookline. is from your question. with Our Raja Please

Kumar Raja

thing enrollments? Hi. ongoing there ongoing some us the it? Europe? unfortunate could color preparing you the I'm situation Omicron you current regards provide enrollments how are the [Indiscernible] worse on might And With that to crowd, And in also Kumar. impact do is for

Joseph Payne

disease deficiency? our are the enrollment a to OTC of speaking therapeutics programs you rare for Are programs

Kumar Raja

Right. Yes.

Joseph Payne

that trial a Okay. multi-dose Yes. Well, what's unique trial. about two this it's Phase is

multiple a of have happen trials. dose participants or because Potentially right. something it's significant because looking curing to that it's there are So functionally the

that our at So reason, thinking least point. this people that's it's for easier at to recruit

add guidance. looking the as we've Kingdom I United it's and in additional three, Belgium We Spain. countries and mentioned think to have We're

waves interrupt COVID surprising to so we long that be okay should with respect of As things, recruitment. can

we're So in for OTC program year. guiding interim the well still we're data that's second some on our for sharing clinical what of this and track half

Kumar Raja

Great. Okay.

[Indiscernible] -- So recruitment in know the we the to over war process? situation you impacting current spill will

Joseph Payne

No.

neighboring don't Ukraine or have so on or So we recruitment like there. countries any in going anything fine that, we're

Kumar Raja

Excellent.

Thank Okay. you.

cystic you done program, this indicate what for CTA to fibrosis applications? remains Regarding the could be

Joseph Payne

Yeah.

QX to the program. all the this that for for the tox the we process studies, a for or guidance So CTA we're tighter case, in in of CTA studies there -enabling have now, IND, And be filed. doing

So other of just previously that of we've you final submissions. support that, terms establishing we're the that's in programs steps data the gone for in toxicology just through these in know, appropriate required

So very that comfortable can the But feel guidance we cystic we there's that confident CTA the data for fibrosis. and nothing atypical about meet collected. for being filing QX

Kumar Raja

Great. Okay.

Sounds great. questions. Thank you taking so much my for

Joseph Payne

Yes, in. calling of you for Thank course.

Operator

Thank you.

Our next Please Fernandez Seamus question is with Guggenheim. proceed your question. with from

Adrian Duffy

guys Thanks Seamus. Hi, the mentioned. question on U.S. taking Adrian congrats for for this the and

this maybe when data? I Sorry share you but got Phase on forward in by disconnect events going I a complete Another ex question ARCT-XXX when but when markets programs, I about or follow-up. it within ARCT-XXX Vincare Arcturus have Arcturus the be XC little may portions are guess, already or maybe asked maybe time next those confident was and and bringing the a trail an appropriate can earlier, and is, emphasis programs how talk in XB - I guess

Joseph Payne

application Vinbiocare we've our of behalf. just did filed in Well, EUA next to milestones an in Okay. or Vietnam, with what's respect timing

looking so And to approved. we're have that

year. other use except With other of that, a expected will some year emergency approval as included be of included or respect just EUA for application. what of honor that later approval first that provided guidance in EUA the we XB beyond application approval as or as sometime the Southeast approval will countries then an that, Our full Once to or And month. the this well course. to and full can we're all question. next in combined we tight looking bolted efficacy of We're is this as Phase providing developing a networked quarter looking respect with so data to great nations with full approval guidance be course, WHO on anticipated data we the by haven't and Asian soon can, and year, approval an And is later whether countries that for that have nations -- or or be be in the this those that Vietnam sort it's that's well. of Vietnam, into the

then those that alignment collecting multiple gain a looking your with So into regulatory to with our well. question, we're we're booster opportunities. to we're not booster address regulatory try regulatory as label only developing with the but Seamus? for strategy agencies strategy Vietnam, -- with And globally, Did other information

Adrian Duffy

has helpful. is X has and I you. program, the since, OTC year. last How Yes, Phase Thank authorization authorized enrollment the identification in And XB you and on that's efforts X the been Phase prioritizing talk think, mid Phase and the how company study? another patient spends

Joseph Payne

starting where as referring success can things. you momentum is side countries COVID and many -- this deficiency recapture we're to in OTC to is So of We're recruitment these starting of on the program. now controlled we're being doing to the that trials, understand

And so the to only Europe some trial, but and to guided not be we've that guidance going efforts starting some our in with we're countries reinvigorate towards Kingdom, adding. and screening Phase we efforts Belgium, recruitment United the in also XB Phase XB, Spain and we're X additional on that there and Phase provided

I interim half well, for the we guiding we're corporation of program. think, we're having we'll as I the to Hope be So second this that biological as data are a think proof-of-concept in not going a some that year. company, just OTC be

Adrian Duffy

Great. Thanks.

Operator

you. Thank

Our question. Seedhouse proceed next with Steve from with James. is Raymond your question Please

Steve Seedhouse

the given guys point? this studies I event-based and ask vaccination to feasible geographies consider event, you want would possibility still OXX, the for you in other and is or there vaccine primary potential rate event-based [Indiscernible] efficacy Singapore, study at

Joseph Payne

or we're to. because respect vaccine talking I trial past efficacy the a with it design to regulatory trials the think think forward. complicated the of But one question a that country depends I going are agency placebo-controlled for on is

to Phase partnered completed with XXX. that sort and respect vaccine that's we've funding for trial any of the that efforts III will trial of trial them there. respect But looking to to a entity a clinical global we be respective we've And design the with late-stage trial. So OXX, with efficacy

Steve Seedhouse

you Thank very Okay. much.

Joseph Payne

Yes.

Operator

you. Thank

question. Arce Wainwright. proceed with Our next Ed H.C. with question Please is from your

Thomas Hoffmann

is Hi. here questions couple afternoon, Ed. everyone. on progress a Good asking the Thomas of for This Congratulations quarter. all this

So given XXX therefore what have as that geographical global hands they mostly it development like question. one out, be? is you a ongoing program, Can vaccine it's And And just still upcoming you discuss Vinbio. of study I sounds with more entity. XXX pointed the in area will this then

Joseph Payne

The geographical for area for which XXX? study,

Thomas Hoffmann

know We XXX. primarily is Vietnam. For in XXX

Joseph Payne

is Yeah. study, to the and clinical sort OXX The provided all to future the trial of study respect that's entity. by global with the be design -- location that of updates going

so advanced, we'll that.XXX in emergency use in We of for more filing to announced is Vietnam. approval, And them looking be course. a today

But vaccine will So going to respect preliminary is that to one's closer XXX. our around on to reaching franchise, be that's be focus approval. with where our

Thomas Hoffmann

what the then outlined, we interim one data? year describe perhaps in the And safety target. of you is or half on the data Understood. perhaps data program still Can question some Is the should efficacy this expect. data about kind it OTC second

Joseph Payne

above hope subset of all data interim we've a is All participants. I right? the Yeah. in of guided the

urea acid OTC is be only the in multiple disease, this itself, safety that in division be course, urea looking And Of at in patients, genesis a with tracked, biomarkers and cycle urea the disorders. to urine. going associated there's we erotic can including or plasma but not are ammonia

concept, So if to guided that the But any proves is interim half data this the of share we'll year. be for it. we've data second what excited out of

Thomas Hoffmann

you the much my Thank again taking forward decision we to EUA next month. look for and so questions Understood.

Joseph Payne

hi say and Thomas, Thanks, them. for Ed Yes. to

Operator

Thank you.

from question is Piper your Yasmeen Our with Rahimi question. proceed with please next Sandler,

Yasmeen Rahimi

Hey Sam.

my and for can manufacturing those data Thanks has as taking up scaled is taking to thanks. have comment on This Vinbiocare Just Andy. you files. you for Do whether my they up? activities see directed seen ramped Thank now Andy, being you question. question. follow-up to the

Andy Sassine

and asking coming for on that back No. Thanks question.

we our of these that indicated to of approval As get in alluded to had we we commentary, manufacturers needed in CMC some runs.

have and you with assume trying also production in the would in with consistent to here So Europe that XX U.S. we're to our for partners. remain a

production And as facility alluded in so be year. we to Vietnam, to later start this able hopefully, to

continue been to with done. we able sharing closely this specific to year, work in to the We haven't hopefully get it but on with their they path are information as them technology guidance when team. getting very transfer to that And

Yasmeen Rahimi

Thank you, Andy.

Andy Sassine

Thanks Yess.

Operator

We have session, will the the turn reached to remarks. end and President question-and-answer over of closing call and the for Payne now CEO Joseph and I

Joseph Payne

at Just or if always, thanks at to it couldn't either to reconnecting in. think any everyone follow-up reach can forward And we questions look can calling for we conference as address and a have you time. of out this IR you you

So we it's bye for now until meet again Bye.

Operator

for time, conference. today's concludes this thank This at your And participation. you may line your disconnect you

Arcturus Therapeutics (ARCT) 1 Mar 222021 Q4 Earnings call transcript